Extracorporeal life support for severe adult respiratory failure.
The past 35 years have provided a wealth of evidence that mechanical ventilation, although potentially life saving, can injure the lungs. Recent evidence suggests that limiting ventilating gas volumes can reduce patient mortality, but may result in progressive parenchymal derecruitment and alveolar hypoventilation, potentially aggravating systemic hypercarbia and hypoxemia. This review summarizes the current recommendations on a controversial, invasive technique termed 'extracorporeal life support' as a means to provide temporary pulmonary support during 'lung-protective' strategies. Extracorporeal life support has been implemented since the origins of cardiopulmonary bypass in the 1950s, but differs in several important ways from cardiopulmonary bypass, including its prolonged duration of application. Because extracorporeal life support serves only to supplement physiological derangements and is not therapeutic, patient selection critically impacts results. Whereas reversible neonatal processes such as meconium aspiration and persistent fetal circulation have fostered clinical trials demonstrating the efficacy of extracorporeal life support, adult cardiopulmonary failure extracorporeal life support trials have proved less compelling. Despite two prospective randomized trials that failed to demonstrate its efficacy, adult extracorporeal life support continues in limited centers of excellence. Adult extracorporeal life support survival rates for respiratory failure average 50% when strict criteria are met, but it remains unclear whether these results represent improved outcomes. Extracorporeal life support is an invasive technique that can provide support to the failing lung. Clinical trials have demonstrated its efficacy in neonatal and pediatric patients, but data in adults are less clear. An ongoing trial in the UK will soon address this important issue.